← 產業報告目錄

Interventional Oncology Market by Devices & Consumables (RF, microwave, cryoablation. embolization), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung), End User (Hospital, Specialty Clinic) - Global Forecast to 2029

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-01-31頁數 456報告編號 MD6975

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The interventional oncology market is projected to reach USD 4.24 billion by 2029 from USD 2.75 billion in 2024, at a CAGR of 9.0% during the forecast period. Interventional oncology, has seen significant growth over the past decade. Progress in minimally invasive techniques and an increase in cancer prevalence rates have contributed significantly to this boom. Initially, the market for interventional oncology was underdeveloped owing to the long-standing use of traditional surgical approaches for cancer; however, growing evidence of safety and efficacy from interventional treatments like TACE, TARE, and thermal ablation sparked interest in using these treatments. These techniques have many advantages, such as shorter recovery times, fewer complications, and better overall patient outcomes compared to conventional surgery. The increasing demand for effective treatments for inoperable tumors, especially liver, lung, and kidney cancers, has driven the growth of the market. “By devices & consumables, embolization devices segment is expected to have the largest market share in the interventional oncology market.” Based on devices & consumables, the market share of embolization devices in the interventional oncology sector is highest, as these are crucial tools in minimally invasive cancer treatments that provide an overwhelming advantage over conventional surgical methods. These devices act by reducing or cutting off the blood flow to the tumor, thus starving the tumor of the oxygen and nutrients needed for growth. The growing trend of embolization procedures, TACE, and radioembolization, which is also called selective internal radiation therapy, can be attributed to their proven success in the treatment of inoperable cancers, especially liver cancer, which remains a significant concern in interventional oncology. Improvements in embolic agents, including drug-eluting beads and radioactive microspheres, have improved accuracy and therapeutic outcomes and are therefore becoming more popular. Such factors as the increased global incidence of cancer, increased awareness of non-invasive treatment options, and shift towards outpatient care models further contribute to the growing use of such devices. “By cancer type, liver cancer segment is expected to have the largest market share in the interventional oncology market.” Based on cancer type, liver cancer is the biggest market share in the interventional oncology segment, primarily due to its increasing global incidence, high mortality rate, and the urgent need for effective, minimally invasive treatment solutions. Hepatocellular carcinoma, the most common form of liver cancer, is closely associated with risk factors such as chronic hepatitis B and C infections, excessive alcohol use, and the growing prevalence of non-alcoholic fatty liver disease. Targeted treatments such as TACE, TARE, and percutaneous ablation in interventional oncology have been very effective in the treatment of unresectable liver cancers. These interventions provide localized tumor control, reduced systemic toxicity, and improved survival outcomes compared to traditional chemotherapy. “By procedure, transcatheter arterial radioembolization (TARE) or selective internal radiation therapy (SIRT) segment is expected to have the largest market share in the interventional oncology market.” Based on procedure, transcatheter arterial radioembolization (TARE), also referred to as selective internal radiation therapy (SIRT), holds the largest market share in the interventional oncology sector due to its demonstrated efficacy in managing both primary and secondary liver cancers, which account for a significant portion of cancer-related mortalities worldwide. This procedure involves injecting microspheres that are infused with radioactive isotopes, most commonly Yttrium-90, directly into the hepatic artery that feeds the tumor. TARE is effective in killing tumor cells with minimal systemic exposure and reduced damage to healthy surrounding tissues by delivering localized radiation. It is becoming increasingly popular because of a superior safety profile, enhanced tolerability, and fewer adverse effects than conventional chemotherapy and external beam radiation therapy. In addition, TARE is particularly useful in patients with unresectable hepatocellular carcinoma and liver metastases from colorectal cancer, in whom alternative treatments are less effective or unavailable. “By end user, hospitals segment is expected to have the largest market share in the interventional oncology market.” Based on end user, transcatheter arterial radioembolization (TARE), also referred to as selective internal radiation therapy (SIRT), holds the largest market share in the interventional oncology sector due to its demonstrated efficacy in managing both primary and secondary liver cancers, which account for a significant portion of cancer-related mortalities worldwide. This procedure involves injecting microspheres that are infused with radioactive isotopes, most commonly Yttrium-90, directly into the hepatic artery that feeds the tumor. TARE is effective in killing tumor cells with minimal systemic exposure and reduced damage to healthy surrounding tissues by delivering localized radiation. It is becoming increasingly popular because of a superior safety profile, enhanced tolerability, and fewer adverse effects than conventional chemotherapy and external beam radiation therapy. In addition, TARE is particularly useful in patients with unresectable hepatocellular carcinoma and liver metastases from colorectal cancer, in whom alternative treatments are less effective or unavailable. “By region, North America region is expected to have the largest market share in the interventional oncology market.” The market share of interventional oncology is dominated by hospitals because of their wide infrastructure, latest technology, and multidisciplinary expertise necessary to perform advanced interventional procedures. Techniques such as TACE, TARE, and tumor ablation are highly specialized and minimally invasive and require access to sophisticated imaging systems, catheterization laboratories, and experienced interventional radiologists. Tertiary care centers and dedicated cancer hospitals have more of such facilities, so these are ideally placed as the first option for interventional oncology treatment. Additionally, a hospital would offer complete treatment; it offers diagnosis, treatment, post-treatment care, and follow-up. This helps in attracting the wide patient spectrum looking for one-stop solutions to treat cancer. A breakdown of the primary participants (supply-side) for the interventional oncology market referred to for this report is provided below: • By Company Type: Tier 1–35%, Tier 2–40%, and Tier 3–25% • By Designation: C-level–20%, Director Level–35%, and Others–45% • By Region: North America–27%, Europe–25%, Asia Pacific–30%, Latin America- 8%, Middle East & Africa-10% . Prominent players in the interventional oncology market are are Siemens Healthineers AG (Varian) (US), Medtronic (Ireland), Boston Scientific Corporation (US), Terumo Corporation (Japan), Merit Medical Systems (US), Johnson & Johnson MedTech (Ethicon) (US), Stryker (US), Teleflex Incorporated (US), AngioDynamics (US), Cook (US), Icecure Medical (Israel), Olympus Corporation (Japan), Imbiotechnologies Ltd (Canada), Medwaves Inc (US), Minimax Medical Limited (China), ABK Biomedical Inc (Canada), RF Medical Co., Ltd (South Korea), Profound Medical (Canada), Surgnova (China), STARmed America (US), Sirtex SIR-Spheres Pty Ltd (US), Accuray Incorporated (US), Guerbet (France), Embolx, Inc (Canada) and Sonablate Corp (US). Research Coverage: The report analyzes the interventional oncology market and aims at estimating the market size and future growth potential of this market based on various segments such as devices & consumables, cancer type, procedure, end user and region. The report also includes a competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies. Reasons to Buy the Report The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall interventional oncology market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities. This report provides insights into the following pointers: • Analysis of key drivers (Rising patient preference for minimally invasive procedure, expansion of cancer patient population, increasing public-private funding and government support for interventional oncology, technological advancements in interventional oncology), restraints (High cost of interventional oncology, unfavorable regulations), opportunities (emerging economies offer high growth potential), challenges (dearth of well-trained and skilled radiologist and oncologist, strong market positioning of alternative therapies) • ZMarket Penetration: It includes extensive information on products offered by the major players in the global the interventional oncology market. The report includes various segments in offering, application, end user and region. • Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global interventional oncology market. • Market Development: Thorough knowledge and analysis of the profitable rising markets by offering, application, end user and region. • Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global the interventional oncology market. • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products, and capacities of the major competitors in the global interventional oncology market.
目錄 Table of Contents
1 INTRODUCTION 38 1.1 STUDY OBJECTIVES 38 1.2 MARKET DEFINITION & SCOPE 38 1.2.1 INCLUSIONS & EXCLUSIONS 39 1.2.2 MARKETS COVERED 40 1.2.3 YEARS CONSIDERED 41 1.2.4 CURRENCY CONSIDERED 41 1.3 STAKEHOLDERS 42 1.4 LIMITATIONS 42 1.5 SUMMARY OF CHANGES 42 2 RESEARCH METHODOLOGY 44 2.1 RESEARCH DATA 44 2.1.1 SECONDARY DATA 45 2.1.1.1 Key data from secondary sources 46 2.1.2 PRIMARY DATA 47 2.1.2.1 Key data from primary sources 48 2.1.2.2 Key industry insights 49 2.2 MARKET SIZE ESTIMATION 51 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 57 2.4 MARKET SHARE ESTIMATION 58 2.5 STUDY ASSUMPTIONS 58 2.6 RESEARCH LIMITATIONS 58 2.6.1 METHODOLOGY-RELATED LIMITATIONS 58 2.7 RISK ASSESSMENT 59 3 EXECUTIVE SUMMARY 60 4 PREMIUM INSIGHTS 65 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN INTERVENTIONAL ONCOLOGY MARKET 65 4.2 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES AND COUNTRY, 2023 66 4.3 INTERVENTIONAL ONCOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 67 4.4 INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2024−2029 67 4.5 INTERVENTIONAL ONCOLOGY MARKET: DEVELOPED VS. EMERGING MARKETS 68   5 MARKET OVERVIEW 69 5.1 INTRODUCTION 69 5.2 MARKET DYNAMICS 69 5.2.1 DRIVERS 70 5.2.1.1 Rising preference for minimally invasive procedures 70 5.2.1.2 Growing prevalence of cancer 70 5.2.1.3 Increasing public-private funding and government support for interventional oncology 71 5.2.1.4 Technological advancements in interventional oncology 71 5.2.2 RESTRAINTS 72 5.2.2.1 High cost of interventional oncology 72 5.2.2.2 Unfavorable regulations 72 5.2.3 OPPORTUNITIES 73 5.2.3.1 Emerging economies offer high-growth potential 73 5.2.4 CHALLENGES 73 5.2.4.1 Dearth of well-trained and skilled radiologists and oncologists 73 5.2.4.2 Strong market position of alternative therapies 74 5.3 INDUSTRY TRENDS 74 5.3.1 INNOVATIONS IN IMAGING AND TREATMENT TECHNOLOGIES 74 5.3.2 INCREASING ADOPTION OF MINIMALLY INVASIVE PROCEDURES 74 5.4 VALUE CHAIN ANALYSIS 75 5.5 TECHNOLOGY ANALYSIS 76 5.5.1 KEY TECHNOLOGIES 76 5.5.1.1 Ablation technologies 76 5.5.1.2 Embolization technologies 76 5.5.2 COMPLEMENTARY TECHNOLOGY 76 5.5.2.1 Laparoscopy 76 5.5.2.2 Diagnostic imaging 76 5.5.3 ADJACENT TECHNOLOGY 77 5.5.3.1 Radiation therapy systems 77 5.5.3.2 Chemotherapy 77 5.6 PORTER’S FIVE FORCES ANALYSIS 77 5.6.1 THREAT OF NEW ENTRANTS 78 5.6.2 THREAT OF SUBSTITUTES 78 5.6.3 BARGAINING POWER OF SUPPLIERS 78 5.6.4 BARGAINING POWER OF BUYERS 78 5.6.5 INTENSITY OF COMPETITIVE RIVALRY 79 5.7 KEY STAKEHOLDERS AND BUYING CRITERIA 79 5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS 79 5.7.2 BUYING CRITERIA 80   5.8 REGULATORY LANDSCAPE 81 5.8.1 KEY REGULATORY BODIES AND GOVERNMENT AGENCIES 81 5.8.2 KEY REGULATORY GUIDELINES 84 5.8.2.1 US 84 5.8.2.2 Canada 85 5.8.2.3 Europe 87 5.8.2.4 Asia Pacific 88 5.8.2.4.1 Japan 88 5.8.2.4.2 China 90 5.8.2.4.3 India 91 5.8.2.5 Brazil 92 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 93 5.10 PATENT ANALYSIS 93 5.10.1 PATENT PUBLICATION TRENDS FOR INTERVENTIONAL ONCOLOGY, JANUARY 2014–DECEMBER 2024 93 5.11 TRADE ANALYSIS 96 5.12 PRICING ANALYSIS 97 5.12.1 AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES, BY KEY PLAYER, 2023 97 5.12.2 AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES, BY KEY PLAYER, 2023 (USD) 97 5.12.3 AVERAGE SELLING PRICE TREND OF INTERVENTIONAL ONCOLOGY DEVICES, BY REGION, 2021–2023 98 5.13 KEY CONFERENCES AND EVENTS, 2025–2026 99 5.14 UNMET NEEDS AND END USER EXPECTATIONS 100 5.14.1 UNMET NEEDS 100 5.15 END USER EXPECTATIONS IN INTERVENTIONAL ONCOLOGY MARKET 101 5.16 ECOSYSTEM 102 5.17 CASE STUDIES 103 5.18 SUPPLY CHAIN ANALYSIS 104 5.19 ADJACENT MARKET ANALYSIS 105 5.20 INTERVENTIONAL ONCOLOGY MARKET, INVESTMENT AND FUNDING SCENARIO, 2020–2023 106 5.21 IMPACT OF GENERATIVE AI ON INTERVENTIONAL ONCOLOGY MARKET 106 6 INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES 107 6.1 INTRODUCTION 108 6.2 EMBOLIZATION DEVICES 108 6.2.1 RADIOEMBOLIC AGENTS 112 6.2.1.1 Precision-targeted therapy for challenging liver cancers to boost market 112   6.2.2 NON-RADIOACTIVE EMBOLIC AGENTS 115 6.2.2.1 Non-radiation emitting agents to propel market 115 6.2.2.2 Microspheres 119 6.2.2.2.1 Surge in prevalence of hepatocellular carcinoma to fuel growth 119 6.2.2.3 Coated beads 122 6.2.2.3.1 Specialized polymer coatings with enhanced ability to bind, absorb, and release chemotherapeutic agents to drive market 122 6.2.2.4 Microparticles 125 6.2.2.4.1 Use in various cancer applications to drive growth 125 6.3 ABLATION DEVICES 128 6.3.1 RADIOFREQUENCY (RF) ABLATION DEVICES 131 6.3.1.1 Effective treatment of small or difficult-to-reach tumors to propel market growth 131 6.3.2 MICROWAVE ABLATION DEVICES 134 6.3.2.1 Simultaneous treatment of multiple lesions to drive market growth 134 6.3.3 CRYOABLATION DEVICES 137 6.3.3.1 Least painful and higher patient compatibility to drive market 137 6.3.4 OTHER ABLATION DEVICES 140 6.4 SUPPORT DEVICES 143 6.4.1 MICROCATHETERS 146 6.4.1.1 Precise delivery of therapeutic agents to tumors to boost market 146 6.4.2 GUIDEWIRES 149 6.4.2.1 Advancements in guidewire construction and launch of new and advanced products to propel market 149 6.4.3 OTHER SUPPORT DEVICES 151 7 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 154 7.1 INTRODUCTION 155 7.2 LIVER CANCER 156 7.2.1 INCREASING DISEASE PREVALENCE AND RISING RESEARCH ACTIVITIES TO DRIVE MARKET GROWTH 156 7.3 KIDNEY CANCER 159 7.3.1 FIRST-LINE THERAPY PRESERVING MORE KIDNEY TISSUE THAN SURGERY TO BOOST MARKET 159 7.4 BREAST CANCER 162 7.4.1 HIGH PRECISION, BETTER COSMETIC OUTCOMES, COST-EFFECTIVENESS, AND GREATER PATIENT COMFORT TO PROPEL MARKET 162 7.5 LUNG CANCER 165 7.5.1 INCREASING NUMBER OF CANCER CASES TO DRIVE DEMAND 165 7.6 BONE CANCER 168 7.6.1 DIRECT ELIMINATION OF TUMORS AND PAIN RELIEF TO FUEL MARKET 168   7.7 PROSTATE CANCER 171 7.7.1 RISING INCIDENCE OF PROSTATE CANCER AND GROWING ADOPTION OF METAL-BASED FIDUCIAL MARKERS TO CONTRIBUTE TO MARKET GROWTH 171 7.8 OTHER CANCER TYPES 174 8 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 177 8.1 INTRODUCTION 178 8.2 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT) 179 8.2.1 GREATER CLINICAL EFFICACY TO DRIVE MARKET GROWTH 179 8.3 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) 182 8.3.1 ABILITY TO TREAT SMALL AND LARGE-SIZED TUMORS TO DRIVE DEMAND 182 8.4 TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE) 185 8.4.1 INCREASING CLINICAL EVIDENCE IN FAVOR OF TARE AND TACE TO RESTRAIN MARKET GROWTH 185 8.5 THERMAL TUMOR ABLATION 188 8.5.1 GROWING CLINICAL EVIDENCE PROVING EFFICACY OF TREATMENT OF VARIOUS TYPES OF CANCERS TO DRIVE MARKET GROWTH 188 8.6 NON-THERMAL TUMOR ABLATION 191 8.6.1 POTENTIAL ALTERNATIVE TO THERMAL TUMOR ABLATION TO BOOST MARKET 191 9 INTERVENTIONAL ONCOLOGY MARKET, BY END USER 194 9.1 INTRODUCTION 195 9.2 HOSPITALS 195 9.2.1 INCREASING NUMBER OF SURGERIES IN IN-PATIENT SETTINGS TO SUPPORT MARKET GROWTH 195 9.3 SPECIALTY CLINICS 199 9.3.1 INCREASING NUMBER OF CANCER CENTERS TO DRIVE MARKET GROWTH 199 9.4 RESEARCH & ACADEMIC INSTITUTES 202 9.4.1 COLLABORATIONS AMONG DEVICE MANUFACTURERS AND SUPPLIERS TO FUEL MARKET 202 10 INTERVENTIONAL ONCOLOGY MARKET, BY REGION 205 10.1 INTRODUCTION 206 10.2 NORTH AMERICA 208 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 215 10.2.2 US 216 10.2.2.1 Rising cancer cases and preference for ablation procedures to boost market 216 10.2.3 CANADA 223 10.2.3.1 Significant rise in cancer cases to drive market growth 223   10.3 EUROPE 229 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 238 10.3.2 GERMANY 239 10.3.2.1 Increase in incidence of cancer and rising geriatric population to fuel market 239 10.3.3 UK 245 10.3.3.1 Increasing awareness and support for cancer-related activities to drive market 245 10.3.4 FRANCE 252 10.3.4.1 Growing geriatric population to support market growth 252 10.3.5 SPAIN 258 10.3.5.1 Increasing government funding for research to support market growth 258 10.3.6 ITALY 265 10.3.6.1 Growing awareness about cancer and treatment options to support market growth 265 10.3.7 REST OF EUROPE 271 10.4 ASIA PACIFIC 278 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 287 10.4.2 JAPAN 288 10.4.2.1 Rising geriatric population and universal healthcare reimbursement to drive market 288 10.4.3 CHINA 294 10.4.3.1 Increasing incidence of cancer to drive market 294 10.4.4 INDIA 301 10.4.4.1 Improving research capabilities and expansion of key players to drive market growth 301 10.4.5 AUSTRALIA 307 10.4.5.1 Rising investments in research and awareness campaigns to support market growth 307 10.4.6 SOUTH KOREA 314 10.4.6.1 Rising R&D and promising clinical trials to positively impact market growth 314 10.4.7 REST OF ASIA PACIFIC 320 10.5 LATIN AMERICA 327 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 334 10.5.2 BRAZIL 335 10.5.2.1 Rising incidence of cancer and improving healthcare infrastructure to fuel market 335 10.5.3 MEXICO 341 10.5.3.1 Increasing awareness campaigns and rising incidence of cancer to drive market growth 341 10.5.4 REST OF LATIN AMERICA 348   10.6 MIDDLE EAST & AFRICA 354 10.6.1 MACROECONOMIC OUTLOOK 361 10.6.2 GCC COUNTRIES 362 10.6.2.1 Broader healthcare modernization initiatives in interventional oncology to drive market 362 10.6.3 REST OF MIDDLE EAST & AFRICA 369 11 COMPETITIVE LANDSCAPE 376 11.1 OVERVIEW 376 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2024 376 11.3 REVENUE ANALYSIS, 2019−2023 378 11.4 MARKET SHARE ANALYSIS, 2023 379 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 382 11.5.1 STARS 382 11.5.2 EMERGING LEADERS 382 11.5.3 PERVASIVE PLAYERS 382 11.5.4 PARTICIPANTS 382 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 384 11.5.5.1 Company footprint 384 11.5.5.2 Region footprint 385 11.5.5.3 Devices & Consumables footprint 386 11.5.5.4 Cancer type footprint 387 11.5.5.5 Procedure footprint 389 11.5.5.6 End user footprint 390 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 391 11.6.1 PROGRESSIVE COMPANIES 391 11.6.2 DYNAMIC COMPANIES 391 11.6.3 STARTING BLOCKS 391 11.6.4 RESPONSIVE COMPANIES 391 11.6.5 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, 2023 393 11.6.5.1 Detailed list of key startups/SMES, 2023 393 11.6.5.2 Competitive benchmarking of key startups/SMEs 393 11.7 VALUATION & FINANCIAL METRICS 394 11.7.1 FINANCIAL METRICS 394 11.7.2 COMPANY VALUATION 394 11.8 BRAND COMPARISON 395 11.9 COMPETITIVE SCENARIO 396 11.9.1 PRODUCT & SERVICE LAUNCHES AND APPROVALS 396 11.9.2 DEALS 396 11.9.3 EXPANSIONS 398   12 COMPANY PROFILES 399 12.1 KEY PLAYERS 399 12.1.1 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC) 399 12.1.1.1 Business overview 399 12.1.1.2 Products/Solutions/Services offered 400 12.1.1.3 Recent developments 401 12.1.1.3.1 Product launches & approvals 401 12.1.1.3.2 Deals 401 12.1.1.4 MnM view 402 12.1.1.4.1 Right to win 402 12.1.1.4.2 Strategic choices 403 12.1.1.4.3 Weaknesses and competitive threats 403 12.1.2 BOSTON SCIENTIFIC CORPORATION 404 12.1.2.1 Business overview 404 12.1.2.2 Products/Solutions/Services offered 405 12.1.2.3 Recent developments 406 12.1.2.3.1 Product launches & approvals 406 12.1.2.3.2 Deals 407 12.1.2.4 MnM view 407 12.1.2.4.1 Right to win 407 12.1.2.4.2 Strategic choices 407 12.1.2.4.3 Weaknesses and competitive threats 407 12.1.3 MEDTRONIC 408 12.1.3.1 Business overview 408 12.1.3.2 Products/Solutions/Services offered 409 12.1.3.3 MnM view 411 12.1.3.3.1 Right to win 411 12.1.3.3.2 Strategic choices 411 12.1.3.3.3 Weaknesses and competitive threats 411 12.1.4 TERUMO CORPORATION 412 12.1.4.1 Business overview 412 12.1.4.2 Products/Solutions/Services offered 413 12.1.4.3 Recent developments 414 12.1.4.3.1 Expansions 414 12.1.4.4 MnM view 414 12.1.4.4.1 Right to win 414 12.1.4.4.2 Strategic choices 414 12.1.4.4.3 Weaknesses and competitive threats 414   12.1.5 MERIT MEDICAL SYSTEMS 415 12.1.5.1 Business overview 415 12.1.5.2 Products/Solutions/Services offered 416 12.1.5.3 Recent developments 417 12.1.5.3.1 Expansions 417 12.1.5.4 MnM view 417 12.1.5.4.1 Right to win 417 12.1.5.4.2 Strategic choices 418 12.1.5.4.3 Weaknesses and competitive threats 418 12.1.6 JOHNSON & JOHNSON MEDTECH (ETHICON) 419 12.1.6.1 Business overview 419 12.1.6.2 Products/Solutions/Services offered 420 12.1.7 TELEFLEX INCORPORATED 421 12.1.7.1 Business overview 421 12.1.7.2 Products/Solutions/Services offered 422 12.1.8 ANGIODYNAMICS 423 12.1.8.1 Business overview 423 12.1.8.2 Products/Solutions/Services offered 424 12.1.8.3 Recent developments 425 12.1.8.3.1 Product launches & approvals 425 12.1.9 STRYKER 426 12.1.9.1 Business overview 426 12.1.9.2 Products/Solutions/Services offered 427 12.1.10 IMBIOTECHNOLOGIES LTD. 428 12.1.10.1 Business overview 428 12.1.10.2 Products/Solutions/Services offered 428 12.1.11 COOK 429 12.1.11.1 Business overview 429 12.1.11.2 Products/Solutions/Services offered 429 12.1.12 ICECURE MEDICAL 430 12.1.12.1 Business overview 430 12.1.12.2 Products/Solutions/Services offered 431 12.1.12.3 Recent developments 432 12.1.12.3.1 Product approvals 432 12.1.12.3.2 Deals 432 12.1.13 MEDWAVES, INC. 434 12.1.13.1 Business overview 434 12.1.13.2 Products/Solutions/Services offered 434 12.1.14 PROFOUND MEDICAL 435 12.1.14.1 Business overview 435 12.1.14.2 Products/Solutions/Services offered 435   12.1.15 RF MEDICAL CO., LTD. 436 12.1.15.1 Business overview 436 12.1.15.2 Products/Solutions/Services offered 436 12.1.16 MINIMAX MEDICAL LIMITED 437 12.1.16.1 Business overview 437 12.1.16.2 Products/Solutions/Services offered 437 12.1.17 ABK BIOMEDICAL INC. 438 12.1.17.1 Business overview 438 12.1.17.2 Products/Solutions/Services offered 438 12.1.18 OLYMPUS CORPORATION 439 12.1.18.1 Business overview 439 12.1.18.2 Products/Solutions/Services offered 440 12.1.19 SURGNOVA 441 12.1.19.1 Business overview 441 12.1.19.2 Products/Solutions/Services offered 441 12.1.20 STARMED AMERICA 442 12.1.20.1 Business overview 442 12.1.20.2 Products/Solutions/Services offered 442 12.2 OTHER PLAYERS 443 12.2.1 SIRTEX SIR-SPHERES PTY LTD. 443 12.2.2 GUERBET 444 12.2.3 ACCURAY INCORPORATED 445 12.2.4 EMBOLX, INC. 446 12.2.5 SONABLATE CORP. 447 13 APPENDIX 448 13.1 DISCUSSION GUIDE 448 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 452 13.3 CUSTOMIZATION OPTIONS 454 13.4 RELATED REPORTS 454 13.5 AUTHOR DETAILS 455
圖表清單 List of Tables & Figures
TABLE 1 STANDARD CURRENCY CONVERSION RATES 41 TABLE 2 RISK ASSESSMENT: INTERVENTIONAL ONCOLOGY MARKET 59 TABLE 3 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES 79 TABLE 4 KEY BUYING CRITERIA FOR EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES 80 TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES 81 TABLE 6 EUROPE: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES 81 TABLE 7 ASIA PACIFIC: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES 82 TABLE 8 LATIN AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES 83 TABLE 9 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES 83 TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION 84 TABLE 11 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 84 TABLE 12 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 85 TABLE 13 JAPAN: PMDA CLASSIFICATION OF ABLATION DEVICES 89 TABLE 14 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA) 89 TABLE 15 CHINA: CLASSIFICATION OF MEDICAL DEVICES 90 TABLE 16 INDIA: CDSCO CLASSIFICATION OF ABLATION DEVICES 92 TABLE 17 LIST OF PATENTS IN INTERVENTIONAL ONCOLOGY MARKET, 2021–2024 95 TABLE 18 IMPORT DATA FOR INTERVENTIONAL ONCOLOGY (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND) 96 TABLE 19 EXPORT DATA FOR INTERVENTIONAL ONCOLOGY (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND) 96 TABLE 20 AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES, BY KEY PLAYER, 2023 (USD) 97 TABLE 21 AVERAGE SELLING PRICE TREND OF INTERVENTIONAL ONCOLOGY DEVICES, BY REGION, 2021–2023 98 TABLE 22 INTERVENTIONAL ONCOLOGY MARKET: KEY CONFERENCES & EVENTS, 2025–2026 99 TABLE 23 END USER EXPECTATIONS FOR EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES 101 TABLE 24 INTERVENTIONAL ONCOLOGY MARKET: ECOSYSTEM ANALYSIS 102 TABLE 25 TREATMENT OF HEPATOCELLULAR CARCINOMA WITH ARTERIOPORTAL SHUNTING USING BALLOON-ASSISTED TRANSARTERIAL YTTRIUM-90 RADIATION SEGMENTECTOMY 103 TABLE 26 RADIOFREQUENCY ABLATION ANALYSIS CASE STUDY 104 TABLE 27 UPPER POLE ANGIOMYOLIPOMA (AML) EMBOLIZATION 104 TABLE 28 INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 108 TABLE 29 INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 108 TABLE 30 INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 109 TABLE 31 INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 109 TABLE 32 INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY REGION, 2019–2023 (USD MILLION) 110 TABLE 33 INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY REGION, 2024–2029 (USD MILLION) 111 TABLE 34 RADIOEMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS 112 TABLE 35 INTERVENTIONAL ONCOLOGY MARKET FOR RADIOEMBOLIC AGENTS, BY REGION, 2019–2023 (USD MILLION) 113 TABLE 36 INTERVENTIONAL ONCOLOGY MARKET FOR RADIOEMBOLIC AGENTS, BY REGION, 2024–2029 (USD MILLION) 114 TABLE 37 NON-RADIOACTIVE EMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS 115 TABLE 38 INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY TYPE, 2019–2023 (USD MILLION) 116 TABLE 39 INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY TYPE, 2024–2029 (USD MILLION) 116 TABLE 40 INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY REGION, 2019–2023 (USD MILLION) 117 TABLE 41 INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY REGION, 2024–2029 (USD MILLION) 118 TABLE 42 INTERVENTIONAL ONCOLOGY MARKET FOR MICROSPHERES, BY REGION, 2019–2023 (USD MILLION) 120 TABLE 43 INTERVENTIONAL ONCOLOGY MARKET FOR MICROSPHERES, BY REGION, 2024–2029 (USD MILLION) 121 TABLE 44 INTERVENTIONAL ONCOLOGY MARKET FOR COATED BEADS, BY REGION, 2019–2023 (USD MILLION) 123 TABLE 45 INTERVENTIONAL ONCOLOGY MARKET FOR COATED BEADS, BY REGION, 2024–2029 (USD MILLION) 124 TABLE 46 MAJOR BRANDS OF MICROCARRIERS 125 TABLE 47 INTERVENTIONAL ONCOLOGY MARKET FOR MICROPARTICLES, BY REGION, 2019–2023 (USD MILLION) 126 TABLE 48 INTERVENTIONAL ONCOLOGY MARKET FOR MICROPARTICLES, BY REGION, 2024–2029 (USD MILLION) 127 TABLE 49 INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 128 TABLE 50 INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 128 TABLE 51 INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION) 129 TABLE 52 INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION) 130 TABLE 53 RADIOFREQUENCY ABLATION DEVICES OFFERED BY MAJOR MARKET PLAYERS 131 TABLE 54 INTERVENTIONAL ONCOLOGY MARKET FOR RADIOFREQUENCY ABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION) 132 TABLE 55 INTERVENTIONAL ONCOLOGY MARKET FOR RADIOFREQUENCY ABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION) 133 TABLE 56 RADIOFREQUENCY ABLATION SYSTEMS, BY REGION, 2023–2029 (THOUSAND UNITS) 134 TABLE 57 INTERVENTIONAL ONCOLOGY MARKET FOR MICROWAVE ABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION) 135 TABLE 58 INTERVENTIONAL ONCOLOGY MARKET FOR MICROWAVE ABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION) 136 TABLE 59 MICROWAVE ABLATION SYSTEMS, BY REGION, 2023–2029 (THOUSAND UNITS) 137 TABLE 60 INTERVENTIONAL ONCOLOGY MARKET FOR CRYOABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION) 138 TABLE 61 INTERVENTIONAL ONCOLOGY MARKET FOR CRYOABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION) 139 TABLE 62 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER ABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION) 141 TABLE 63 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER ABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION) 142 TABLE 64 INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 143 TABLE 65 INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 143 TABLE 66 INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY REGION, 2019–2023 (USD MILLION) 144 TABLE 67 INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY REGION, 2024–2029 (USD MILLION) 145 TABLE 68 INTERVENTIONAL ONCOLOGY MARKET FOR MICROCATHETERS, BY REGION, 2019–2023 (USD MILLION) 147 TABLE 69 INTERVENTIONAL ONCOLOGY MARKET FOR MICROCATHETERS, BY REGION, 2024–2029 (USD MILLION) 148 TABLE 70 INTERVENTIONAL ONCOLOGY MARKET FOR GUIDEWIRES, BY REGION, 2019–2023 (USD MILLION) 150 TABLE 71 INTERVENTIONAL ONCOLOGY MARKET FOR GUIDEWIRES, BY REGION, 2024–2029 (USD MILLION) 151 TABLE 72 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER SUPPORT DEVICES, BY REGION, 2019–2023 (USD MILLION) 152 TABLE 73 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER SUPPORT DEVICES, BY REGION, 2024–2029 (USD MILLION) 153 TABLE 74 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 155 TABLE 75 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 155 TABLE 76 INTERVENTIONAL ONCOLOGY MARKET FOR LIVER CANCER, BY REGION, 2019–2023 (USD MILLION) 157 TABLE 77 INTERVENTIONAL ONCOLOGY MARKET FOR LIVER CANCER, BY REGION, 2024–2029 (USD MILLION) 158 TABLE 78 INTERVENTIONAL ONCOLOGY MARKET FOR KIDNEY CANCER, BY REGION, 2019–2023 (USD MILLION) 160 TABLE 79 INTERVENTIONAL ONCOLOGY MARKET FOR KIDNEY CANCER, BY REGION, 2024–2029 (USD MILLION) 161 TABLE 80 INTERVENTIONAL ONCOLOGY MARKET FOR BREAST CANCER, BY REGION, 2019–2023 (USD MILLION) 163 TABLE 81 INTERVENTIONAL ONCOLOGY MARKET FOR BREAST CANCER, BY REGION, 2024–2029 (USD MILLION) 164 TABLE 82 INTERVENTIONAL ONCOLOGY MARKET FOR LUNG CANCER, BY REGION, 2019–2023 (USD MILLION) 166 TABLE 83 INTERVENTIONAL ONCOLOGY MARKET FOR LUNG CANCER, BY REGION, 2024–2029 (USD MILLION) 167 TABLE 84 INTERVENTIONAL ONCOLOGY MARKET FOR BONE CANCER, BY REGION, 2019–2023 (USD MILLION) 169 TABLE 85 INTERVENTIONAL ONCOLOGY MARKET FOR BONE CANCER, BY REGION, 2024–2029 (USD MILLION) 170 TABLE 86 INTERVENTIONAL ONCOLOGY MARKET FOR PROSTATE CANCER, BY REGION, 2019–2023 (USD MILLION) 172 TABLE 87 INTERVENTIONAL ONCOLOGY MARKET FOR PROSTATE CANCER, BY REGION, 2024–2029 (USD MILLION) 173 TABLE 88 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER CANCER TYPES, BY REGION, 2019–2023 (USD MILLION) 175 TABLE 89 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER CANCER TYPES, BY REGION, 2024–2029 (USD MILLION) 176 TABLE 90 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 178 TABLE 91 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 178 TABLE 92 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT), BY REGION, 2019–2023 (USD MILLION) 180 TABLE 93 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT), BY REGION, 2024–2029 (USD MILLION) 181 TABLE 94 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE), BY REGION, 2019–2023 (USD MILLION) 183 TABLE 95 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE), BY REGION, 2024–2029 (USD MILLION) 184 TABLE 96 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE), BY REGION, 2019–2023 (USD MILLION) 186 TABLE 97 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE), BY REGION, 2024–2029 (USD MILLION) 187 TABLE 98 INTERVENTIONAL ONCOLOGY MARKET FOR THERMAL TUMOR ABLATION, BY REGION, 2019–2023 (USD MILLION) 189 TABLE 99 INTERVENTIONAL ONCOLOGY MARKET FOR THERMAL TUMOR ABLATION, BY REGION, 2024–2029 (USD MILLION) 190 TABLE 100 INTERVENTIONAL ONCOLOGY MARKET FOR NON-THERMAL TUMOR ABLATION, BY REGION, 2019–2023 (USD MILLION) 192 TABLE 101 INTERVENTIONAL ONCOLOGY MARKET FOR NON-THERMAL TUMOR ABLATION, BY REGION, 2024–2029 (USD MILLION) 193 TABLE 102 INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 195 TABLE 103 INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 195 TABLE 104 INTERVENTIONAL ONCOLOGY MARKET FOR HOSPITALS, BY REGION, 2019–2023 (USD MILLION) 197 TABLE 105 INTERVENTIONAL ONCOLOGY MARKET FOR HOSPITALS, BY REGION, 2024–2029 (USD MILLION) 198 TABLE 106 INTERVENTIONAL ONCOLOGY MARKET FOR SPECIALTY CLINICS, BY REGION, 2019–2023 (USD MILLION) 200 TABLE 107 INTERVENTIONAL ONCOLOGY MARKET FOR SPECIALTY CLINICS, BY REGION, 2024–2029 (USD MILLION) 201 TABLE 108 INTERVENTIONAL ONCOLOGY MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2019–2023 (USD MILLION) 203 TABLE 109 INTERVENTIONAL ONCOLOGY MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2024–2029 (USD MILLION) 204 TABLE 110 INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2019–2023 (USD MILLION) 207 TABLE 111 INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2024–2029 (USD MILLION) 207 TABLE 112 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2023 (USD MILLION) 209 TABLE 113 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024–2029 (USD MILLION) 209 TABLE 114 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 209 TABLE 115 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 210 TABLE 116 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 210 TABLE 117 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 210 TABLE 118 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 211 TABLE 119 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 211 TABLE 120 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 211 TABLE 121 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 212 TABLE 122 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 212 TABLE 123 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 212 TABLE 124 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 213 TABLE 125 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 213 TABLE 126 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 214 TABLE 127 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 214 TABLE 128 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 215 TABLE 129 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 215 TABLE 130 US: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 217 TABLE 131 US: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 217 TABLE 132 US: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 217 TABLE 133 US: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 218 TABLE 134 US: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 218 TABLE 135 US: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 218 TABLE 136 US: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 219 TABLE 137 US: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 219 TABLE 138 US: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 219 TABLE 139 US: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 220 TABLE 140 US: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 220 TABLE 141 US: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 221 TABLE 142 US: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 221 TABLE 143 US: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 222 TABLE 144 US: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 222 TABLE 145 US: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 222 TABLE 146 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 223 TABLE 147 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 224 TABLE 148 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 224 TABLE 149 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 224 TABLE 150 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 225 TABLE 151 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 225 TABLE 152 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 225 TABLE 153 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 226 TABLE 154 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 226 TABLE 155 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 226 TABLE 156 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 227 TABLE 157 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 227 TABLE 158 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 228 TABLE 159 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 228 TABLE 160 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 229 TABLE 161 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 229 TABLE 162 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2023 (USD MILLION) 231 TABLE 163 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024–2029 (USD MILLION) 231 TABLE 164 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 232 TABLE 165 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 232 TABLE 166 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 232 TABLE 167 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 233 TABLE 168 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 233 TABLE 169 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 233 TABLE 170 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 234 TABLE 171 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 234 TABLE 172 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 234 TABLE 173 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 235 TABLE 174 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 235 TABLE 175 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 236 TABLE 176 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 236 TABLE 177 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 237 TABLE 178 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 237 TABLE 179 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 238 TABLE 180 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 239 TABLE 181 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 240 TABLE 182 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 240 TABLE 183 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 240 TABLE 184 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 241 TABLE 185 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 241 TABLE 186 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 241 TABLE 187 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 242 TABLE 188 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 242 TABLE 189 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 242 TABLE 190 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 243 TABLE 191 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 243 TABLE 192 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 244 TABLE 193 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 244 TABLE 194 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 245 TABLE 195 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 245 TABLE 196 UK: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 246 TABLE 197 UK: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 246 TABLE 198 UK: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 246 TABLE 199 UK: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 247 TABLE 200 UK: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 247 TABLE 201 UK: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 247 TABLE 202 UK: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 248 TABLE 203 UK: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 248 TABLE 204 UK: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 248 TABLE 205 UK: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 249 TABLE 206 UK: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 249 TABLE 207 UK: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 250 TABLE 208 UK: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 250 TABLE 209 UK: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 251 TABLE 210 UK: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 251 TABLE 211 UK: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 251 TABLE 212 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 252 TABLE 213 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 253 TABLE 214 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 253 TABLE 215 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 253 TABLE 216 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 254 TABLE 217 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 254 TABLE 218 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 254 TABLE 219 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 255 TABLE 220 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 255 TABLE 221 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 255 TABLE 222 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 256 TABLE 223 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 256 TABLE 224 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 257 TABLE 225 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 257 TABLE 226 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 258 TABLE 227 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 258 TABLE 228 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 259 TABLE 229 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 259 TABLE 230 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 259 TABLE 231 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 260 TABLE 232 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 260 TABLE 233 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 260 TABLE 234 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 261 TABLE 235 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 261 TABLE 236 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 261 TABLE 237 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 262 TABLE 238 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 262 TABLE 239 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 263 TABLE 240 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 263 TABLE 241 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 264 TABLE 242 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 264 TABLE 243 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 264 TABLE 244 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 265 TABLE 245 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 266 TABLE 246 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 266 TABLE 247 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 266 TABLE 248 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 267 TABLE 249 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 267 TABLE 250 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 267 TABLE 251 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 268 TABLE 252 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 268 TABLE 253 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 268 TABLE 254 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 269 TABLE 255 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 269 TABLE 256 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 270 TABLE 257 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 270 TABLE 258 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 271 TABLE 259 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 271 TABLE 260 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 272 TABLE 261 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 272 TABLE 262 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 272 TABLE 263 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 273 TABLE 264 REST OF EUROPE INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 273 TABLE 265 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 273 TABLE 266 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 274 TABLE 267 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 274 TABLE 268 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 274 TABLE 269 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 275 TABLE 270 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 275 TABLE 271 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 276 TABLE 272 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 276 TABLE 273 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 277 TABLE 274 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 277 TABLE 275 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 277 TABLE 276 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2023 (USD MILLION) 280 TABLE 277 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024–2029 (USD MILLION) 280 TABLE 278 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 281 TABLE 279 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 281 TABLE 280 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 281 TABLE 281 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 282 TABLE 282 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 282 TABLE 283 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 282 TABLE 284 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 283 TABLE 285 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 283 TABLE 286 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 283 TABLE 287 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 284 TABLE 288 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 284 TABLE 289 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 285 TABLE 290 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 285 TABLE 291 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 286 TABLE 292 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 286 TABLE 293 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 287 TABLE 294 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 288 TABLE 295 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 289 TABLE 296 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 289 TABLE 297 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 289 TABLE 298 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 290 TABLE 299 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 290 TABLE 300 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 290 TABLE 301 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 291 TABLE 302 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 291 TABLE 303 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 291 TABLE 304 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 292 TABLE 305 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 292 TABLE 306 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 293 TABLE 307 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 293 TABLE 308 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 294 TABLE 309 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 294 TABLE 310 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 295 TABLE 311 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 295 TABLE 312 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 295 TABLE 313 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 296 TABLE 314 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 296 TABLE 315 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 296 TABLE 316 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 297 TABLE 317 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 297 TABLE 318 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 297 TABLE 319 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 298 TABLE 320 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 298 TABLE 321 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 299 TABLE 322 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 299 TABLE 323 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 300 TABLE 324 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 300 TABLE 325 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 300 TABLE 326 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 301 TABLE 327 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 302 TABLE 328 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 302 TABLE 329 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 302 TABLE 330 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 303 TABLE 331 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 303 TABLE 332 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 303 TABLE 333 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 304 TABLE 334 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 304 TABLE 335 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 304 TABLE 336 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 305 TABLE 337 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 305 TABLE 338 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 306 TABLE 339 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 306 TABLE 340 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 307 TABLE 341 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 307 TABLE 342 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 308 TABLE 343 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 308 TABLE 344 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 308 TABLE 345 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 309 TABLE 346 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 309 TABLE 347 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 309 TABLE 348 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 310 TABLE 349 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 310 TABLE 350 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 310 TABLE 351 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 311 TABLE 352 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 311 TABLE 353 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 312 TABLE 354 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 312 TABLE 355 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 313 TABLE 356 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 313 TABLE 357 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 314 TABLE 358 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 314 TABLE 359 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 315 TABLE 360 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 315 TABLE 361 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 315 TABLE 362 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 316 TABLE 363 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 316 TABLE 364 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 316 TABLE 365 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 317 TABLE 366 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 317 TABLE 367 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 317 TABLE 368 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 318 TABLE 369 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 318 TABLE 370 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 319 TABLE 371 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 319 TABLE 372 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 320 TABLE 373 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 320 TABLE 374 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 321 TABLE 375 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 321 TABLE 376 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 321 TABLE 377 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 322 TABLE 378 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 322 TABLE 379 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 322 TABLE 380 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 323 TABLE 381 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 323 TABLE 382 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 323 TABLE 383 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 324 TABLE 384 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 324 TABLE 385 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 325 TABLE 386 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 325 TABLE 387 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 326 TABLE 388 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 326 TABLE 389 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 327 TABLE 390 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2023 (USD MILLION) 327 TABLE 391 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024–2029 (USD MILLION) 328 TABLE 392 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 328 TABLE 393 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 328 TABLE 394 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 329 TABLE 395 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 329 TABLE 396 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 329 TABLE 397 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 330 TABLE 398 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 330 TABLE 399 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 330 TABLE 400 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 331 TABLE 401 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 331 TABLE 402 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 331 TABLE 403 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 332 TABLE 404 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 332 TABLE 405 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 333 TABLE 406 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 333 TABLE 407 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 334 TABLE 408 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 335 TABLE 409 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 336 TABLE 410 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 336 TABLE 411 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 336 TABLE 412 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 337 TABLE 413 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 337 TABLE 414 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 337 TABLE 415 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 338 TABLE 416 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 338 TABLE 417 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 338 TABLE 418 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 339 TABLE 419 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 339 TABLE 420 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 340 TABLE 421 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 340 TABLE 422 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 341 TABLE 423 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 341 TABLE 424 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 342 TABLE 425 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 342 TABLE 426 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 342 TABLE 427 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 343 TABLE 428 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 343 TABLE 429 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 343 TABLE 430 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 344 TABLE 431 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 344 TABLE 432 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 344 TABLE 433 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 345 TABLE 434 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 345 TABLE 435 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 346 TABLE 436 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 346 TABLE 437 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 347 TABLE 438 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 347 TABLE 439 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 348 TABLE 440 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 348 TABLE 441 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 349 TABLE 442 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 349 TABLE 443 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 349 TABLE 444 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 350 TABLE 445 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 350 TABLE 446 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 350 TABLE 447 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 351 TABLE 448 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 351 TABLE 449 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 351 TABLE 450 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 352 TABLE 451 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 352 TABLE 452 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 353 TABLE 453 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 353 TABLE 454 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 354 TABLE 455 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 354 TABLE 456 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2023 (USD MILLION) 355 TABLE 457 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024–2029 (USD MILLION) 355 TABLE 458 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 355 TABLE 459 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 356 TABLE 460 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 356 TABLE 461 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 356 TABLE 462 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 357 TABLE 463 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 357 TABLE 464 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 357 TABLE 465 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 358 TABLE 466 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 358 TABLE 467 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 358 TABLE 468 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 359 TABLE 469 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 359 TABLE 470 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 360 TABLE 471 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 360 TABLE 472 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 361 TABLE 473 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 361 TABLE 474 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 363 TABLE 475 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 363 TABLE 476 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 364 TABLE 477 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 364 TABLE 478 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 364 TABLE 479 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 365 TABLE 480 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 365 TABLE 481 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 365 TABLE 482 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 366 TABLE 483 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 366 TABLE 484 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 366 TABLE 485 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 367 TABLE 486 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 367 TABLE 487 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 368 TABLE 488 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 368 TABLE 489 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 369 TABLE 490 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 369 TABLE 491 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 370 TABLE 492 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 370 TABLE 493 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 370 TABLE 494 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 371 TABLE 495 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 371 TABLE 496 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 371 TABLE 497 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 372 TABLE 498 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 372 TABLE 499 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 372 TABLE 500 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION) 373 TABLE 501 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION) 373 TABLE 502 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION) 374 TABLE 503 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION) 374 TABLE 504 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 375 TABLE 505 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 375 TABLE 506 STRATEGIES ADOPTED BY KEY PLAYERS IN INTERVENTIONAL ONCOLOGY MARKET, JANUARY 2021–DECEMBER 2024 377 TABLE 507 INTERVENTIONAL ONCOLOGY MARKET: DEGREE OF COMPETITION 380 TABLE 508 INTERVENTIONAL ONCOLOGY MARKET: REGION FOOTPRINT 385 TABLE 509 INTERVENTIONAL ONCOLOGY MARKET: DEVICES & CONSUMABLES FOOTPRINT 386 TABLE 510 INTERVENTIONAL ONCOLOGY MARKET: CANCER TYPE FOOTPRINT 387 TABLE 511 INTERVENTIONAL ONCOLOGY MARKET: PROCEDURE FOOTPRINT 389 TABLE 512 INTERVENTIONAL ONCOLOGY MARKET: END USER FOOTPRINT 390 TABLE 513 INTERVENTIONAL ONCOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/ SMES, 2023 393 TABLE 514 INTERVENTIONAL ONCOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 393 TABLE 515 INTERVENTIONAL ONCOLOGY MARKET: PRODUCT & SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024 396 TABLE 516 INTERVENTIONAL ONCOLOGY MARKET: DEALS, JANUARY 2021–DECEMBER 2024 396 TABLE 517 INTERVENTIONAL ONCOLOGY MARKET: EXPANSIONS, JANUARY 2021–DECEMBER 2024 398 TABLE 518 SIEMENS HEALTHINEERS AG (VARIAN): COMPANY OVERVIEW 399 TABLE 519 SIEMENS HEALTHINEERS AG (VARIAN): PRODUCTS/SOLUTIONS/ SERVICES OFFERED 400 TABLE 520 SIEMENS HEALTHINEERS AG (VARIAN): PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024 401 TABLE 521 SIEMENS HEALTHINEERS AG (VARIAN): DEALS, JANUARY 2021–DECEMBER 2024 401 TABLE 522 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 404 TABLE 523 BOSTON SCIENTIFIC CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 405 TABLE 524 BOSTON SCIENTIFIC CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024 406 TABLE 525 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2021–DECEMBER 2024 407 TABLE 526 MEDTRONIC: COMPANY OVERVIEW 408 TABLE 527 MEDTRONIC: PRODUCTS/SOLUTIONS/SERVICES OFFERED 409 TABLE 528 TERUMO CORPORATION: COMPANY OVERVIEW 412 TABLE 529 TERUMO CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 413 TABLE 530 TERUMO CORPORATION: EXPANSIONS, JANUARY 2021– DECEMBER 2024 414 TABLE 531 MERIT MEDICAL SYSTEMS: COMPANY OVERVIEW 415 TABLE 532 MERIT MEDICAL SYSTEMS: PRODUCTS/SOLUTIONS/SERVICES OFFERED 416 TABLE 533 MERIT MEDICAL SYSTEMS: EXPANSIONS, JANUARY 2021– DECEMBER 2024 417 TABLE 534 JOHNSON & JOHNSON MEDTECH (ETHICON): COMPANY OVERVIEW 419 TABLE 535 JOHNSON & JOHNSON MEDTECH (ETHICON): PRODUCTS/SOLUTIONS/ SERVICES OFFERED 420 TABLE 536 TELEFLEX INCORPORATED: COMPANY OVERVIEW 421 TABLE 537 TELEFLEX INCORPORATED: PRODUCTS/SOLUTIONS/SERVICES OFFERED 422 TABLE 538 ANGIODYNAMICS: COMPANY OVERVIEW 423 TABLE 539 ANGIODYNAMICS: PRODUCTS/SOLUTIONS/SERVICES OFFERED 424 TABLE 540 ANGIODYNAMICS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024 425 TABLE 541 STRYKER: COMPANY OVERVIEW 426 TABLE 542 STRYKER: PRODUCTS/SOLUTIONS/SERVICES OFFERED 427 TABLE 543 IMBIOTECHNOLOGIES LTD.: COMPANY OVERVIEW 428 TABLE 544 IMBIOTECHNOLOGIES LTD.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 428 TABLE 545 COOK: COMPANY OVERVIEW 429 TABLE 546 COOK: PRODUCTS/SOLUTIONS/SERVICES OFFERED 429 TABLE 547 ICECURE MEDICAL: COMPANY OVERVIEW 430 TABLE 548 ICECURE MEDICAL: PRODUCTS/SOLUTIONS/SERVICES OFFERED 431 TABLE 549 ICECURE MEDICAL LTD.: PRODUCT APPROVALS 432 TABLE 550 ICECURE MEDICAL LTD.: DEALS 432 TABLE 551 MEDWAVES, INC.: COMPANY OVERVIEW 434 TABLE 552 MEDWAVES INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 434 TABLE 553 PROFOUND MEDICAL: COMPANY OVERVIEW 435 TABLE 554 PROFOUND MEDICAL: PRODUCTS/SOLUTIONS/SERVICES OFFERED 435 TABLE 555 RF MEDICAL CO., LTD.: COMPANY OVERVIEW 436 TABLE 556 RF MEDICAL CO., LTD.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 436 TABLE 557 MINIMAX MEDICAL LIMITED: COMPANY OVERVIEW 437 TABLE 558 MINIMAX MEDICAL LIMITED: PRODUCTS/SOLUTIONS/SERVICES OFFERED 437 TABLE 559 ABK BIOMEDICAL INC.: COMPANY OVERVIEW 438 TABLE 560 ABK BIOMEDICAL INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 438 TABLE 561 OLYMPUS CORPORATION: COMPANY OVERVIEW 439 TABLE 562 OLYMPUS CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 440 TABLE 563 SURGNOVA: COMPANY OVERVIEW 441 TABLE 564 SURGNOVA: PRODUCTS/SOLUTIONS/SERVICES OFFERED 441 TABLE 565 STARMED AMERICA: COMPANY OVERVIEW 442 TABLE 566 STARMED AMERICA: PRODUCTS/SOLUTIONS/SERVICES OFFERED 442 TABLE 567 SIRTEX SIR-SPHERES PTY LTD.: COMPANY OVERVIEW 443 TABLE 568 GUERBET: COMPANY OVERVIEW 444 TABLE 569 ACCURAY: COMPANY OVERVIEW 445 TABLE 570 EMBOLX, INC.: COMPANY OVERVIEW 446 TABLE 571 SONABLATE CORP.: COMPANY OVERVIEW 447 FIGURE 1 INTERVENTIONAL ONCOLOGY MARKET SEGMENTATION 40 FIGURE 2 RESEARCH DESIGN 44 FIGURE 3 PRIMARY SOURCES 47 FIGURE 4 BREAKDOWN OF INTERVIEWS WITH EXPERTS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 49 FIGURE 5 BREAKDOWN OF INTERVIEWS WITH EXPERTS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 50 FIGURE 6 BREAKDOWN OF INTERVIEWS WITH EXPERTS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 50 FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 51 FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: SIEMENS HEALTHINEERS AG (2023) 52 FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: INTERVENTIONAL ONCOLOGY MARKET (2023) 53 FIGURE 10 TOP-DOWN APPROACH 53 FIGURE 11 ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2029) 55 FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 56 FIGURE 13 DATA TRIANGULATION METHODOLOGY 57 FIGURE 14 EMBOLIZATION DEVICES SEGMENT TO DOMINATE INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD (USD MILLION) 60 FIGURE 15 LIVER CANCER TYPE SEGMENT TO LEAD MARKET DURING FORECAST PERIOD (USD MILLION) 61 FIGURE 16 THERMAL TUMOR ABLATION SEGMENT TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD (USD MILLION) 62 FIGURE 17 HOSPITALS SEGMENT TO DOMINATE INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD (USD MILLION) 63 FIGURE 18 NORTH AMERICA ACCOUNTED FOR LARGEST SHARE OF INTERVENTIONAL ONCOLOGY MARKET IN 2023 64 FIGURE 19 GROWING DEMAND FOR INTERVENTIONAL ONCOLOGY TO DRIVE MARKET 65 FIGURE 20 EMBOLIZATION DEVICES ACCOUNTED FOR LARGEST SHARE OF INTERVENTIONAL ONCOLOGY MARKET IN 2023 66 FIGURE 21 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 67 FIGURE 22 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD 67 FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 68 FIGURE 24 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN INTERVENTIONAL ONCOLOGY MARKET 69 FIGURE 25 VALUE CHAIN ANALYSIS: MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE 75 FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES 79 FIGURE 27 KEY BUYING CRITERIA FOR EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES 80 FIGURE 28 PREMARKET NOTIFICATION: 510(K) APPROVALS FOR MEDICAL DEVICES 85 FIGURE 29 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES 86 FIGURE 30 EUROPE: CE APPROVAL PROCESS FOR MEDICAL DEVICES 88 FIGURE 31 REVENUE SHIFT IN INTERVENTIONAL ONCOLOGY MARKET 93 FIGURE 32 PATENT PUBLICATION TRENDS, JANUARY 2014–DECEMBER 2024 93 FIGURE 33 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR INTERVENTIONAL ONCOLOGY, JANUARY 2014–DECEMBER 2024 94 FIGURE 34 TOP APPLICANT JURISDICTIONS FOR INTERVENTIONAL ONCOLOGY PATENTS, JANUARY 2014–DECEMBER 2024 94 FIGURE 35 AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES, BY KEY PLAYER, 2023 97 FIGURE 36 END USER EXPECTATIONS IN EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES 101 FIGURE 37 INTERVENTIONAL ONCOLOGY MARKET: ECOSYSTEM 103 FIGURE 38 INTERVENTIONAL ONCOLOGY MARKET: SUPPLY CHAIN ANALYSIS 105 FIGURE 39 ADJACENT MARKETS TO INTERVENTIONAL ONCOLOGY MARKET 105 FIGURE 40 INVESTMENT/VENTURE CAPITAL SCENARIO IN INTERVENTIONAL ONCOLOGY MARKET, 2020–2023 106 FIGURE 41 CHINA TO GROW AT HIGHEST CAGR IN INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD 206 FIGURE 42 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT 208 FIGURE 43 EUROPE: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT 230 FIGURE 44 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT 279 FIGURE 45 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN INTERVENTIONAL ONCOLOGY MARKET,2019−2023 378 FIGURE 46 INTERVENTIONAL ONCOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2023 379 FIGURE 47 INTERVENTIONAL ONCOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 383 FIGURE 48 INTERVENTIONAL ONCOLOGY MARKET: COMPANY FOOTPRINT 384 FIGURE 49 INTERVENTIONAL ONCOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 392 FIGURE 50 EV/EBITDA OF KEY VENDORS 394 FIGURE 51 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 394 FIGURE 52 INTERVENTIONAL ONCOLOGY MARKET: COMPARATIVE BRAND ANALYSIS 395 FIGURE 53 SIEMENS HEALTHINEERS AG (VARIAN): COMPANY SNAPSHOT (2024) 400 FIGURE 54 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023) 405 FIGURE 55 MEDTRONIC: COMPANY SNAPSHOT (2024) 409 FIGURE 56 TERUMO CORPORATION: COMPANY SNAPSHOT (2024) 413 FIGURE 57 MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT (2023) 416 FIGURE 58 JOHNSON & JOHNSON MEDTECH (ETHICON): COMPANY SNAPSHOT (2023) 420 FIGURE 59 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2023) 422 FIGURE 60 ANGIODYNAMICS: COMPANY SNAPSHOT (2024) 424 FIGURE 61 STRYKER: COMPANY SNAPSHOT (2023) 427 FIGURE 62 ICECURE MEDICAL LTD.: COMPANY SNAPSHOT (2023) 431 FIGURE 63 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2024) 440

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們